These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 24121175)
1. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas. Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175 [TBL] [Abstract][Full Text] [Related]
2. Utility of uroplakin II expression as a marker of urothelial carcinoma. Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628 [TBL] [Abstract][Full Text] [Related]
3. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890 [TBL] [Abstract][Full Text] [Related]
4. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations. Esheba GE; Longacre TA; Atkins KA; Higgins JP Am J Surg Pathol; 2009 Mar; 33(3):347-53. PubMed ID: 19092634 [TBL] [Abstract][Full Text] [Related]
5. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung. Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579 [TBL] [Abstract][Full Text] [Related]
6. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449 [TBL] [Abstract][Full Text] [Related]
7. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Li W; Liang Y; Deavers MT; Kamat AM; Matin SF; Dinney CP; Czerniak B; Guo CC Am J Clin Pathol; 2014 Dec; 142(6):864-71. PubMed ID: 25389341 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical profile of the penile urethra and differential expression of GATA3 in urothelial versus squamous cell carcinomas of the penile urethra. Chaux A; Han JS; Lee S; Gonzalez-Roibon N; Sharma R; Burnett AL; Cubilla AL; Netto GJ Hum Pathol; 2013 Dec; 44(12):2760-7. PubMed ID: 24134931 [TBL] [Abstract][Full Text] [Related]
9. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma. Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315 [TBL] [Abstract][Full Text] [Related]
10. Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder. Klopfer K; Delahunt B; Adamson M; Samaratunga H Anticancer Res; 2014 Nov; 34(11):6779-84. PubMed ID: 25368291 [TBL] [Abstract][Full Text] [Related]
11. GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin. Bezerra SM; Lotan TL; Faraj SF; Karram S; Sharma R; Schoenberg M; Bivalacqua TJ; Netto GJ Hum Pathol; 2014 Aug; 45(8):1682-7. PubMed ID: 24925221 [TBL] [Abstract][Full Text] [Related]